Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. Their lead product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).
Autoimmune PAP is a disease that belongs to a family of distinct, rare lung diseases collectively referred to as PAP. Autoimmune PAP represents about 90% of all patients with PAP. The estimated prevalence of aPAP is 7 cases per million people in the U.S. and 6 cases per million in Japan, with similar or higher prevalence reported elsewhere in the world.
